Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 4,875 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $22.72, for a total value of $110,760.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.03, for a total transaction of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total transaction of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.64, for a total transaction of $76,245.00.

Enliven Therapeutics Stock Down 0.9 %

ELVN stock opened at $24.49 on Thursday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -11.18 and a beta of 1.05. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $26.00. The stock’s fifty day simple moving average is $17.82 and its 200-day simple moving average is $14.96.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Mizuho began coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently added to or reduced their stakes in ELVN. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at approximately $157,000. China Universal Asset Management Co. Ltd. acquired a new position in Enliven Therapeutics during the 4th quarter worth $66,000. AJOVista LLC bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth about $28,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after purchasing an additional 2,208 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.